Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian Ciurea

Showing results (11-20 of 130) with videos related to

Pageof 13
Sort By:
Current Opinion in Microbiology|September 11, 2004
Public, private and non-specific antibodies induced by non-cytopathic viral infectionsMike Recher, Lukas Hunziker, Adrian Ciurea, et al.
Arthritis and Rheumatism|May 2, 2007
Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort studyStéphane Genevay, Axel Finckh, Adrian Ciurea, et al.
Scandinavian Journal of Occupational Therapy|May 11, 2010
Development and psychometric properties of a joint protection self-efficacy scaleKarin Niedermann, Adrian Forster, Adrian Ciurea, et al.
Arthritis Care & Research|July 14, 2018
Barriers and Facilitators of Vigorous Cardiorespiratory Training in Axial Spondyloarthritis: Surveys Among Patients, Physiotherapists, and RheumatologistsKarin Niedermann, Irina Nast, Adrian Ciurea, et al.
Clinical Rheumatology|February 11, 2026
Anti-CD74 IgA is not associated with modic changes in the Northern Finland Birth CohortAnnik Steimer, Friederike Schulze, Juhani Määttä, et al.
RMD Open|July 12, 2022
Prediction of histology by B-mode and PD-mode ultrasound across different joint locations and diseasesRaphael Micheroli, Chantal Pauli, Kristina Bürki, et al.
Joint Bone Spine|May 18, 2010
Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patientsAxel Finckh, Jean Dudler, Felix Wermelinger, et al.
Rheumatology (Oxford, England)|April 13, 2021
Discontinuation of biologic DMARDs in a real-world population of patients with rheumatoid arthritis in remission: outcome and risk factorsSimone Arnold, Veronika K Jaeger, Almut Scherer, et al.
Praxis|April 10, 2014
[Limitations of medicine:diagnosis and therapy of <<inflammatory>> back pain]Verena Scharer, Roland Hafner, Adrian Ciurea, et al.
Arthritis and Rheumatism|May 1, 2009
Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritisSophie Martin Du Pan, Silvia Dehler, Adrian Ciurea, et al.
Pageof 13

Showing results (11-20 of 130) with videos related to

Sort By:
Pageof 13
Current Opinion in Microbiology|September 11, 2004
Public, private and non-specific antibodies induced by non-cytopathic viral infectionsMike Recher, Lukas Hunziker, Adrian Ciurea, et al.
Arthritis and Rheumatism|May 2, 2007
Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort studyStéphane Genevay, Axel Finckh, Adrian Ciurea, et al.
Scandinavian Journal of Occupational Therapy|May 11, 2010
Development and psychometric properties of a joint protection self-efficacy scaleKarin Niedermann, Adrian Forster, Adrian Ciurea, et al.
Arthritis Care & Research|July 14, 2018
Barriers and Facilitators of Vigorous Cardiorespiratory Training in Axial Spondyloarthritis: Surveys Among Patients, Physiotherapists, and RheumatologistsKarin Niedermann, Irina Nast, Adrian Ciurea, et al.
Clinical Rheumatology|February 11, 2026
Anti-CD74 IgA is not associated with modic changes in the Northern Finland Birth CohortAnnik Steimer, Friederike Schulze, Juhani Määttä, et al.
RMD Open|July 12, 2022
Prediction of histology by B-mode and PD-mode ultrasound across different joint locations and diseasesRaphael Micheroli, Chantal Pauli, Kristina Bürki, et al.
Joint Bone Spine|May 18, 2010
Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patientsAxel Finckh, Jean Dudler, Felix Wermelinger, et al.
Rheumatology (Oxford, England)|April 13, 2021
Discontinuation of biologic DMARDs in a real-world population of patients with rheumatoid arthritis in remission: outcome and risk factorsSimone Arnold, Veronika K Jaeger, Almut Scherer, et al.
Praxis|April 10, 2014
[Limitations of medicine:diagnosis and therapy of <<inflammatory>> back pain]Verena Scharer, Roland Hafner, Adrian Ciurea, et al.
Arthritis and Rheumatism|May 1, 2009
Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritisSophie Martin Du Pan, Silvia Dehler, Adrian Ciurea, et al.
Pageof 13